Is AOD-9604 Legal in Tennessee? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Get Complicated?

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, specifically amino acids 176 through 191. Researchers originally studied it for obesity treatment because early animal data suggested it could stimulate lipolysis and inhibit lipogenesis without producing the insulin resistance associated with full-length hGH. The compound reached Phase IIb clinical trials in humans, sponsored by Metabolic Pharmaceuticals Ltd., before the FDA declined to approve its New Drug Application (NDA) in 2007.

That regulatory history is the root of every legal question asked about AOD-9604 today.

The NDA Failure and Its Downstream Consequences

When the FDA declined the NDA, AOD-9604 did not acquire an approved indication. Without approval, it cannot be marketed as a drug product in the United States. A compound sitting outside the approved-drug system has only two legal routes to patients: it can qualify as a legitimate compounded drug under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), or it can be sold strictly for laboratory research with no human administration.

The FDA's 503A framework governs traditional compounding pharmacies that fill patient-specific prescriptions. The 503B framework covers outsourcing facilities that produce larger batches for office stock without patient-specific prescriptions. Both frameworks depend on whether the peptide appears on lists maintained or approved by the FDA, and that is where AOD-9604's status took a significant turn in 2023.

The 2023 FDA Bulk List Decision

In late 2022 and into 2023, the FDA evaluated numerous peptides that had been circulating in the compounding market. AOD-9604 was among the substances the FDA declined to include on its 503A Bulks List, meaning 503A pharmacies lost their clearest legal basis to compound it for individually prescribed patients. The FDA's reasoning, consistent with its Interim Policy on Compounding Using Bulk Drug Substances, is that a substance must meet specific criteria related to clinical need, safety, and whether an approved alternative exists before it earns a place on that list. [1]

This decision does not make possession or use of AOD-9604 a federal crime for an individual patient, but it significantly narrows the pharmacy pathway through which a Tennessee resident can legitimately obtain it.

Federal Regulatory Framework: FDA, FTC, and DEA

Understanding Tennessee's situation requires sorting out three overlapping federal agencies first.

FDA Authority Over Compounded Drugs

The FDA regulates drugs. Compounded drugs are treated as unapproved new drugs that receive enforcement discretion when compounding pharmacies follow the rules in 503A or 503B of the FD&C Act. [2] The FDA has stated that substances not on the 503A Bulks List and not otherwise approved cannot be routinely compounded by traditional pharmacies.

The agency's 2023 guidance on bulk drug substances describes a category system: substances nominated for the 503A list are either placed on Category 1 (acceptable to compound), Category 2 (not acceptable), or remain under review. AOD-9604's position in this framework affects every downstream step in Tennessee. [3]

DEA Scheduling Status

AOD-9604 is not listed as a Schedule I through V controlled substance under the Controlled Substances Act. That means no criminal penalty attaches to possession at the federal level purely on the basis of DEA scheduling. This is often misread to mean the peptide is freely legal. It is not. A substance can be unscheduled yet still be an unapproved drug whose manufacture and distribution violate the FD&C Act. [4]

FTC and the Research-Chemical Market

Some vendors sell AOD-9604 labeled "for research use only, not for human consumption." The Federal Trade Commission and FDA have both warned that this labeling does not immunize a seller if the substance is actually marketed for human use. Buying from these sources carries real legal and safety risk for the consumer, because there is no pharmaceutical-grade quality control, no sterility testing, and no physician oversight.

Tennessee State Law: What Applies Locally

Tennessee does not have a statute that names AOD-9604 specifically. No entry for it exists in the Tennessee Code Annotated drug scheduling tables (Title 39, Chapter 17, Part 4). That absence matters. It means Tennessee has not independently criminalized AOD-9604 at the state level.

Tennessee Board of Pharmacy Rules

The Tennessee Board of Pharmacy regulates compounding pharmacies operating within the state under Rules of the Tennessee Board of Pharmacy, Chapter 1140-03. Tennessee-licensed compounding pharmacies must comply with USP standards (USP <797> for sterile compounding, USP <795> for non-sterile) and must operate within the federal 503A framework if they are traditional pharmacies. [5]

Because the FDA has not placed AOD-9604 on the 503A Bulks List, a Tennessee-based 503A pharmacy operating by the rules should not be compounding it for individual prescriptions. A pharmacy doing so anyway is operating outside federal guidance, which creates liability for the pharmacist and prescriber alike.

Tennessee Medical Practice Act and Prescriber Authority

Tennessee physicians are governed by the Tennessee Medical Practice Act (Tenn. Code Ann. § 63-6-101 et seq.) and the Board of Medical Examiners. The Medical Practice Act does not enumerate which peptides a physician may or may not prescribe; it requires that prescribing reflect "good medical practice" supported by clinical judgment and documentation. [6]

A Tennessee physician who orders AOD-9604 must be prepared to document the medical rationale, confirm the source pharmacy's compliance status, and recognize that prescribing a substance whose compounding basis is legally tenuous exposes both the prescriber and patient to risk.

Tennessee Telehealth Parity Law

Tennessee's 2023 telehealth parity legislation (Tenn. Code Ann. § 56-7-1002) requires that commercial insurers cover telehealth visits comparably to in-person visits for eligible services. For AOD-9604 specifically, insurance coverage is essentially zero because the compound lacks an approved indication, but the parity law means a Tennessee patient can have a full prescribing consultation with a licensed Tennessee physician via telehealth without driving to a clinic. The prescription itself, if issued, must still comply with all federal compounding rules. [7]

The 503B Outsourcing Facility Pathway

The most defensible legal route to compounded AOD-9604 in Tennessee runs through an FDA-registered 503B outsourcing facility.

How 503B Differs From 503A

Section 503B facilities are registered with the FDA and subject to current Good Manufacturing Practice (cGMP) standards. They can produce drugs in bulk without patient-specific prescriptions, selling to licensed practitioners for office use or dispensing. Critically, 503B facilities operate under a different list mechanism than 503A pharmacies; the FDA evaluates whether a substance raises concerns under the "essentially a copy" rule and other criteria. [8]

Some 503B outsourcing facilities have continued to produce certain peptides during the period of regulatory uncertainty. Whether a specific 503B facility can lawfully compound AOD-9604 depends on their internal legal review and FDA inspection history. A physician or clinic in Tennessee sourcing from a 503B facility should request documentation of the facility's FDA registration, their GMP inspection status, and the specific legal basis their compliance team has established for this compound.

What a Tennessee Clinic Needs to Document

A Tennessee provider running a legitimate AOD-9604 protocol through a 503B supply chain should maintain records covering at minimum:

• Confirmed FDA registration number of the 503B outsourcing facility
• Certificate of Analysis (CoA) for each lot, confirming identity, potency, and sterility
• Signed informed consent documenting that AOD-9604 is not FDA-approved and that long-term safety data in humans are limited
• Chart notes connecting the prescription to a specific clinical finding (e.g., documented excess adiposity with BMI above a defined threshold, failed first-line interventions)
• Notation of the 2023 FDA bulk-list status and the facility's stated compliance basis

Without this documentation stack, the prescriber's position in any Board of Medical Examiners inquiry is weak.

Clinical Evidence: What the Science Actually Shows

AOD-9604's regulatory history cannot be separated from its evidentiary record. The FDA's NDA rejection in 2007 was not arbitrary.

Human Trial Data

Metabolic Pharmaceuticals Ltd. Conducted a 12-week, double-blind, placebo-controlled Phase IIb trial in overweight adults. The trial tested oral AOD-9604 doses ranging from 1 mg to 54 mg daily. At the 1 mg dose, subjects showed a statistically modest reduction in body fat compared to placebo. Higher doses did not produce greater weight loss, and no dose produced clinically meaningful outcomes by the thresholds the FDA required for approval. The company did not publish the full dataset in a peer-reviewed journal indexed on PubMed, which limits independent verification. [9]

Animal studies, primarily in Zucker fa/fa rats and in C57BL/6J obese mice, showed more strong fat-loss signals. The peptide appeared to activate beta-3 adrenergic receptors and inhibit acetyl-CoA carboxylase. A 2001 paper by Ng et al. In the journal Molecular and Cellular Endocrinology characterized these mechanisms at the molecular level. [10]

What the Evidence Does Not Support

No long-term human safety trial (beyond 12 weeks) has been published for AOD-9604. No randomized controlled trial has assessed cardiovascular outcomes, IGF-1 levels over time, or immune effects in humans. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy, published in 2015 and updated in subsequent communications, does not mention AOD-9604 as an evidence-based option. [11]

Contrast this with semaglutide 2.4 mg (Wegovy), where the STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [12] AOD-9604 has no trial of comparable size, duration, or rigor in humans.

Clinician Perspective on the Evidence Gap

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital and a past president of the Obesity Society, has stated in published commentary that "peptides marketed for weight loss outside the approved-drug framework present a real challenge: patients are often paying out of pocket for compounds with very thin human evidence." [11] That caution applies directly to AOD-9604.

How to Access AOD-9604 Legally in Tennessee: Step-by-Step

The path is narrow but real. Here is the sequence a Tennessee patient and provider should follow.

Step 1: Establish Care With a Licensed Tennessee Provider

The prescribing physician must be licensed in Tennessee and must conduct a compliant medical evaluation. That evaluation can happen via telehealth under Tennessee's parity rules, but it must include a history, review of prior weight-management interventions, relevant labs (fasting glucose, lipid panel, thyroid function), and documentation of clinical need.

Step 2: Confirm the Pharmacy's Compliance Status

Before writing the prescription, the provider should call or email the compounding pharmacy and ask two direct questions. First: are you a 503A or 503B facility? Second: what is your documented legal basis for compounding AOD-9604 given the FDA's current bulk-list status? A 503A pharmacy that cannot cite a clear exception should not be used. A 503B facility should be able to produce its FDA registration and explain its compliance framework.

Step 3: Obtain Informed Consent

The patient must sign an informed consent that covers the compound's unapproved status, the limited human clinical evidence, the absence of FDA oversight of the specific product batch (unless from a cGMP 503B facility), and the cost (typically $150 to $400 per month, paid out of pocket).

Step 4: Monitor and Document Response

A responsible prescriber sets defined outcome metrics before starting therapy. Body composition by DXA or calibrated bioelectrical impedance at baseline and at 8 to 12 weeks gives objective data. If no measurable response occurs, continued prescribing is harder to justify clinically.

Red Flags: What to Avoid in Tennessee

Not every vendor or clinic claiming to offer AOD-9604 is operating within the law. Several patterns signal a problematic setup.

Online sales without a prescription are illegal under federal law regardless of how the product is labeled. A site selling AOD-9604 as a "research chemical" with a checkout cart that ships to Tennessee consumers is operating outside the law, and the product may fail basic quality standards.

Clinics prescribing without a physical or telehealth examination violate Tennessee's prescribing standards. A provider who texts a prescription for a peptide without any documented assessment has not met the threshold required by the Tennessee Medical Practice Act.

Pharmacies that cannot or will not produce a Certificate of Analysis for the specific lot being dispensed should not be used. Sterile injectables without verified sterility testing carry infection risk.

IGF-1 and Growth Hormone Axis: A Note on Safety Monitoring

AOD-9604 is marketed specifically as a fragment of hGH that lacks the full IGF-1-stimulating activity of the parent molecule. The 2001 Ng et al. Mechanistic paper and Metabolic Pharmaceuticals' trial data both indicated that the 176-191 fragment does not raise IGF-1 or fasting glucose in humans at the doses studied. [10]

That finding is reassuring but does not eliminate monitoring obligations. Any prescriber using a growth-hormone-axis peptide in a patient with a history of malignancy, active proliferative retinopathy, or elevated IGF-1 at baseline should proceed with extreme caution or not at all. Baseline IGF-1 measurement costs roughly $50 to $80 at standard reference laboratories and takes about 48 hours to result.